» Articles » PMID: 38985311

The Clinical Picture of Castleman Disease: a Systematic Review and Meta-analysis

Overview
Journal Blood Adv
Specialty Hematology
Date 2024 Jul 10
PMID 38985311
Authors
Affiliations
Soon will be listed here.
Abstract

Castleman disease (CD) encompasses a spectrum of rare disorders, including unicentric CD (UCD), idiopathic multicentric CD (iMCD), and human herpesvirus 8-associated MCD (HHV8+ MCD). We performed a systematic review of publications reporting ≥5 cases of CD between 1995 and 2021, following preferred reporting items for systematic reviews and meta-analyses guidelines, to describe and compare subtypes. We extracted data on clinical symptoms and laboratory parameters as stated in international consensus diagnostic criteria for iMCD and estimated the frequency of each criterion using meta-analyses. We analyzed 32 studies describing 559 UCD, 1023 iMCD, and 416 HHV8+ MCD cases. Although many symptoms and laboratory abnormalities occurred at similar rates in patients with iMCD and HHV8+ MCD, patients with HHV8+ MCD had significantly higher rates of constitutional symptoms (46.6% vs 98.6%; P = .038) and splenomegaly (48.2% vs 89.2%; P = .031). Renal dysfunction was significantly more common in patients with iMCD than in patients with HHV8+ MCD before adjustment (36.9% vs 17.4%; P = .04; adjusted P = .1). Patients with UCD had lower rates of symptoms and laboratory abnormalities, although these were present in 20% of patients and were particularly pronounced in pediatric UCD. There are many similarities in the symptomatology of iMCD and HHV8+ MCD; many patients experience constitutional symptoms and organ dysfunction. Differences between these subtypes likely reflect differences in pathophysiology and/or comorbidity burdens.

Citing Articles

Unicentric Castleman Disease Coexisting With Type 2 Autoimmune Pancreatitis: A Case Report Mimicking Pancreatic Cancer and Near-Whipple Surgery.

Konlack Mekontso J, Olliverrie A, Ren J, Stefanishina V, Karim S, Khan S ACG Case Rep J. 2025; 12(3):e01635.

PMID: 40040853 PMC: 11878988. DOI: 10.14309/crj.0000000000001635.


Massive endobronchial hemorrhage leading to Cardiac arrest during EBUS-TBNA: a case of successful resuscitation.

Hong P, Huang M, Cai L, Chen Y, Guo Y, Zhang X BMC Pulm Med. 2025; 25(1):42.

PMID: 39863848 PMC: 11765929. DOI: 10.1186/s12890-025-03503-5.

References
1.
Hoffmann C, Schmid H, Muller M, Teutsch C, van Lunzen J, Esser S . Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011; 118(13):3499-503. DOI: 10.1182/blood-2011-02-333633. View

2.
Kojima M, Nakamura N, Tsukamoto N, Otuski Y, Shimizu K, Itoh H . Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28 cases. Int J Surg Pathol. 2008; 16(4):391-8. DOI: 10.1177/1066896908315812. View

3.
Gopal S, Liomba N, Montgomery N, Moses A, Kaimila B, Nyasosela R . Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi. J Int AIDS Soc. 2015; 18:20122. PMC: 4524888. DOI: 10.7448/IAS.18.1.20122. View

4.
Zhu S, Yu Y, Zhang Y, Sun J, Han D, Li J . Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients. Med Oncol. 2013; 30(1):492. DOI: 10.1007/s12032-013-0492-0. View

5.
Zhang Y, Suo S, Yang H, Zhou X, You L, Yu W . Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study. J Cancer Res Clin Oncol. 2020; 146(2):357-365. PMC: 6985045. DOI: 10.1007/s00432-019-03120-w. View